JANUARY 26 JAN 26
2019
SATURDAY SAT

Stanford Review of the 60th Annual American Society of Hematology Meeting 2019

Ritz Carlton Hotel, Half Moon Bay, CA

A Continuing Medical Education Conference presented by the Department of Medicine, Division of Hematology at the Stanford University School of Medicine.

Statement of Need

The 2019 Stanford Review of the 60th Annual ASH Conference will highlight cutting-edge research and data on hematologic disorders presented at the conference, as well as provide participants with updated treatment algorithms and strategies for optimizing the care of their patients. The symposium will utilize a variety of learning modalities, including case studies, panel discussions, and audience response questions, to facilitate meaningful interactions between expert faculty presenters and symposium participants.

Target Audience

This is a local/regional conference designed to meet the educational needs of Hematologists, Nurse Practitioners, Physician Assistants, Nurses, Pharmacists and Allied Health Professionals who care for patients with benign and malignant hematologic diseases.

Learning Objectives

At the conclusion of this activity, participants should be able to:

  • Evaluate the use of new chemotherapeutics and biologic regimens in subpopulations of acute myeloid leukemia patients based on patient clinical and genetic prognostic factors and treatment goals
  • Apply treatment strategies that optimally utilize JAK inhibitors and other novel agents in patients with myelofibrosis, PV, and other relevant MPNs
  • Use prognostic models to risk stratify MPN patients for therapy
  • Analyze the role of new biologics for the treatment of advanced systematic mastocytosis
  • Evaluate optimal sequencing and combinations of novel biologicals for CLL
  • Discuss the current role of Minimal Residue Disease (MRD) testing for the detection of molecular abnormalities
  • Incorporate available therapeutic options for patients with low- or high-risk myelodysplastic syndromes and utilize the IPSS-R prognostic scoring system along with new mutation data to classify patients for treatment
  • Determine the best combination regimens, novel agents, and new antibody therapies for different populations of newly diagnosed and relapsed/refractory myeloma patients, including patients who are transplant eligible and transplant ineligible
  • Evaluate the results of phase II/III trials in Hodgkin and non-Hodgkin lymphomas
  • Incorporate appropriate emerging novel therapies for patients with hemophilia
  • Evaluate new treatment indications for direct oral anticoagulants for patients with non-malignant hematology
  • Discuss new therapeutic directions in sickle cell disease and disorders of iron homeostasis

Course Directors

Jason Gotlib, MD, MS

Course Director
Professor of Medicine
Division of Hematology

Michaela Liedtke, MD

Course Co-Director
Associate Professor of Medicine
Division of Hematology

A Continuing Medical Education Activity

Presented by the Division of Hematology at the Stanford University School of Medicine.

Sponsored by the Stanford University School of Medicine

Conference Contact

For conference related questions please contact

Debbie Aube
CME Conference Coordinator
(650) 724-5318
debbie.aube@stanford.edu

For general questions, please send us an email or call us
stanfordcme@stanford.edu
(650) 497-8554


Mailing List

New activities are added regularly.  Join our mailing list to receive notifications about activities of interest to you.